I know a thing or 2 and stem cell therapies require to come in...

I know a thing or 2 and stem cell therapies require to come in from the fringe.

MSB has worked highly professionally visionary and very strategically to be far from from the fringe and to be at the forefront of registered stem cell therapeutics.

it is having a tough time with the MSC side as the little buggers are not so homogenous.

this to me leaves a cloud over the head of MSC indications given differing MOA and need for assays to prove concept and consistency might well be needed.

I do hope MSB well however the ride as a shareholder for me was less than thrilling and is a shame that such great science is marred by poor management - thus it has paid off one class action and is still facing another one.